Showing results (1-10 of 57) with videos related to
Sort By:
Pageof 6
Best Practice & Research. Clinical Haematology|November 23, 2015
Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemiaAnjali AdvaniBest Practice & Research. Clinical Haematology|December 14, 2022
When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?Anjali AdvaniEuropean Journal of Haematology|February 3, 2017
Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemiaSwapna Thota, Anjali AdvaniBritish Journal of Haematology|November 11, 2014
Current status of antibody therapy in ALLJing Ai, Anjali AdvaniBest Practice & Research. Clinical Haematology|December 6, 2021
Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?Ibrahim Aldoss, Anjali Advani, Vinod PullarkatAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Recent Advances in Managing Acute Lymphoblastic LeukemiaDaniel J DeAngelo, Elias Jabbour, Anjali AdvaniAmerican Journal of Hematology|August 30, 2008
Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemiaMatt Kalaycio, Anjali Advani, Brad Pohlman, et al.Leukemia Research|March 9, 2024
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemiaSharon Zhong, Heena Kurish, Robert Walchack, et al.Leukemia & Lymphoma|May 13, 2006
The role of post-remission chemotherapy for older patients with acute myelogenous leukemiaRony M Abou-Jawde, Ronald Sobecks, Brad Pohlman, et al.Medical Oncology (Northwood, London, England)|October 22, 2025
Optimization of upfront therapy for adult acute lymphoblastic leukemia: a paradigm shift toward immunotherapyAmr Hanbali, Mostafa Saleh, Mohamed Kharfan-Dabaja, et al.Pageof 6